Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Obesity Right
  3. Zepbound (tirzepatide) injection Right
  4. Has dysesthesia been reported in patients taking Zepbound® (tirzepatide)?
Search Zepbound (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Zepbound ® (tirzepatide) injection

2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Has dysesthesia been reported in patients taking Zepbound® (tirzepatide)?

In the SURMOUNT-1 and -2 studies, dysesthesia was reported by 0.2%, 0.2%, and 0.4% of participants treated with tirzepatide 5 mg, 10 mg, and 15 mg, respectively. Dysesthesia was reported by 0.1% of participants receiving placebo.

US_cFAQ_TZPCWM510_DYSESTHESIA_T2D_CWM
US_cFAQ_TZPCWM510_DYSESTHESIA_T2D_CWMen-US

See important safety information, including boxed warning, in the attached prescribing information.

Dysesthesia

Dysesthesia is a touch-based disorder that can result in feelings of pain, itchiness, tingling, shock, burning, and other uncomfortable sensations in the skin.1

In 2 weight reduction trials in adults with obesity or overweight, with or without type 2 diabetes, dysesthesia occurred more frequently among patients receiving tirzepatide (5 mg 0.2%, 10 mg 0.2%, 15 mg 0.4%) than placebo (0.1%).2

Enclosed Prescribing Information

ZEPBOUND® (tirzepatide) injection, for subcutaneous use, Lilly

References

1Dysesthesia. Cleveland Clinic. Updated May 12, 2023. Accessed November 13, 2024. https://my.clevelandclinic.org/health/symptoms/24989-dysesthesia

2Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.

Date of Last Review: November 13, 2024

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.44 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly